News

The Scientific Committee of Innovative Medicine Initiative (IMI), published a very interesting recommendation paper on future research needs regarding rare diseases. IRDiRC has been mentioned as a global consortium in rare disease research that involves stakeholders from Africa, Asia, Australia, North America, and Europe. Click here to download the pdf version of the article.

August 4th 2020 Dr. Philip John (P.J.) Brooks has been elected as new Chair of the Interdisciplinary Scientific Committee (ISC). Dr. Brooks is a Program Director in the NIH National Center for Advancing Translational Sciences (NCATS) Office of Rare Diseases Research (ORDR).  Dr. Brooks received his Ph.D. in neurobiology from the University of North Carolina at Chapel Hill. […]

June 25, 2020 To further encourage the development of treatments for rare diseases, EMA will waive all fees for scientific advice for academia developing orphan medicines.The academic sector plays an important role in the development of innovative medicines. Their scientific research is often at the source of novel methodologies and innovative medicines with a potential to benefit patients with rare diseases.Early […]

June 23rd 2020 The Food and Drug Administration’s (FDA) Office of Orphan Products Development (OOPD) is pleased to announce availability of funds for fiscal years (FY) 2021 – FY 2022 to support innovative and efficient clinical trials for rare diseases and conditions.  These studies are intended to provide acceptable data to the FDA that will […]

June 2, 2020 THE CALL IS CLOSED Share your expertise with IRDiRC  The Consortium is seeking experts to join its Diagnostics Scientific Committee to work together to the achievement of IRDiRC Goal 1 for 2027:  All patients coming to medical attention with a suspected rare disease will be diagnosed within one year if their disorder is known in the medical literature; […]